Tevogen Bio Partners with Databricks to Advance AI-Driven Immunotherapy Target Prediction Platform
• Tevogen Bio has commissioned Databricks to accelerate development of PredicTcell, its proprietary AI-driven target prediction model for precision immunotherapy.
• The collaboration will enhance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor engagement, based on Tevogen's ExacTcell platform.
• This partnership represents the third pillar of Tevogen.AI's foundation, alongside Microsoft Research and Tevogen Bio's own clinical expertise, aimed at transforming precision medicine.
Tevogen Bio Files Patent for Novel T Cell Vaccine Targeting Entire Viral Genomes
• Tevogen Bio has filed a USPTO patent for a unique T cell vaccine designed to target entire viral genomes, potentially overcoming mutation-based resistance seen with traditional vaccines.
• The vaccine leverages Tevogen's proprietary Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate T cell responses, differentiating it from conventional B cell-focused vaccines.
• Initially prioritized for national security and military applications against biological threats, the company plans transparent development with potential for broader public health applications.
Tevogen Bio Secures In-House Cell Therapy Production Facility to Accelerate T Cell Therapeutics Development
• Tevogen Bio has finalized an agreement with CD8 Technology Services to develop a turn-key facility supporting both pre-clinical research and GMP cell therapy production capabilities.
• The strategic move aims to overcome capital barriers typically faced in building GMP capabilities at scale, while maintaining operational agility and controlling costs in developing off-the-shelf CD8+ T cell therapeutics.
• This facility agreement follows Tevogen's earlier financing activities in 2024, including a $6 million Series C Preferred Stock investment and access to a $36 million line of credit, positioning the company for accelerated pipeline advancement.
Tevogen Bio Presents ExacTcell Platform to BARDA as Potential Rapid-Response Viral Countermeasure
• Tevogen Bio met with BARDA TechWatch team to showcase their ExacTcell technology, highlighting its potential as a scalable medical countermeasure against emerging viral threats.
• The company's platform demonstrated positive safety results in proof-of-concept trials for TVGN 489, incorporating AI capabilities in its development process.
• As a clinical-stage biotech firm, Tevogen Bio aims to develop off-the-shelf CD8+ cytotoxic T lymphocyte therapies for infectious diseases, cancers, and neurological disorders.
Tevogen Bio CEO Highlights Commitment to Patient Accessibility and Business Model
• Tevogen Bio's CEO, Dr. Saadi, reaffirmed his dedication to making therapeutics accessible to patients through the company's innovative business model.
• The company's officers hold nearly 79% of outstanding shares, demonstrating confidence in Tevogen Bio's potential and long-term vision.
• Tevogen Bio is advancing its ExacTcell™ technology to develop off-the-shelf T cell therapies for infectious diseases, cancers, and neurological disorders.
• Tevogen Bio anticipates sharing updates on its pipeline, including a $1 billion oncology forecast for the launch year, indicating strong growth expectations.
Tevogen Bio's TVGN 489 Shows Promise in High-Risk COVID-19 Patients
• Tevogen Bio's TVGN 489, an allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes immunotherapy, demonstrates promising results in a Phase I clinical trial.
• The trial showed symptom improvement and viral elimination in high-risk COVID-19 patients, including those immunocompromised, with no disease progression or Long COVID development.
• TVGN 489 was well-tolerated across all tested doses, with no significant adverse events and did not interfere with endogenous anti-SARS-CoV-2 responses.
• The study observed persistence of donor-derived CTLs through the 6-month follow-up, suggesting potential for sustained therapeutic effect.
© Copyright 2025. All Rights Reserved by MedPath